Literature DB >> 20116937

Pathogenesis of hepatitis B virus infection.

F V Chisari1, M Isogawa, S F Wieland.   

Abstract

The adaptive immune response is thought to be responsible for viral clearance and disease pathogenesis during hepatitis B virus infection. It is generally acknowledged that the humoral antibody response contributes to the clearance of circulating virus particles and the prevention of viral spread within the host while the cellular immune response eliminates infected cells. The T cell response to the hepatitis B virus (HBV) is vigorous, polyclonal and multispecific in acutely infected patients who successfully clear the virus and relatively weak and narrowly focussed in chronically infected patients, suggesting that clearance of HBV is T cell dependent. The pathogenetic and antiviral potential of the cytotoxic T lymphocyte (CTL) response to HBV has been proven by the induction of a severe necroinflammatory liver disease following the adoptive transfer of HBsAg specific CTL into HBV transgenic mice. Remarkably, the CTLs also purge HBV replicative intermediates from the liver by secreting type 1 inflammatory cytokines thereby limiting virus spread to uninfected cells and reducing the degree of immunopathology required to terminate the infection. Persistent HBV infection is characterized by a weak adaptive immune response, thought to be due to inefficient CD4+ T cell priming early in the infection and subsequent development of a quantitatively and qualitatively ineffective CD8+ T cell response. Other factors that could contribute to viral persistence are immunological tolerance, mutational epitope inactivation, T cell receptor antagonism, incomplete down-regulation of viral replication and infection of immunologically privileged tissues. However, these pathways become apparent only in the setting of an ineffective immune response, which is, therefore, the fundamental underlying cause. Persistent infection is characterized by chronic liver cell injury, regeneration, inflammation, widespread DNA damage and insertional deregulation of cellular growth control genes, which, collectively, lead to cirrhosis of the liver and hepatocellular carcinoma. Copyright 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20116937      PMCID: PMC2888709          DOI: 10.1016/j.patbio.2009.11.001

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  106 in total

1.  The hepatitis B virus MHBst167 protein is a pleiotropic transactivator mediating its effect via ubiquitous cellular transcription factors.

Authors:  W H Caselmann; M Renner; V Schlüter; P H Hofschneider; R Koshy; M Meyer
Journal:  J Gen Virol       Date:  1997-06       Impact factor: 3.891

2.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.

Authors:  L G Guidotti; T Ishikawa; M V Hobbs; B Matzke; R Schreiber; F V Chisari
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

3.  The hepatitis B virus large surface protein (LHBs) is a transcriptional activator.

Authors:  E Hildt; G Saher; V Bruss; P H Hofschneider
Journal:  Virology       Date:  1996-11-01       Impact factor: 3.616

4.  Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice.

Authors:  S N Huang; F V Chisari
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

5.  Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver.

Authors:  L G Guidotti; P Borrow; M V Hobbs; B Matzke; I Gresser; M B Oldstone; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

6.  The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

Authors:  B Rehermann; C Ferrari; C Pasquinelli; F V Chisari
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

Review 7.  Hepatitis B virus immunopathogenesis.

Authors:  F V Chisari; C Ferrari
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

8.  High-level hepatitis B virus replication in transgenic mice.

Authors:  L G Guidotti; B Matzke; H Schaller; F V Chisari
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes.

Authors:  L V Tsui; L G Guidotti; T Ishikawa; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

10.  The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.

Authors:  B Rehermann; P Fowler; J Sidney; J Person; A Redeker; M Brown; B Moss; A Sette; F V Chisari
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more
  144 in total

Review 1.  Role of interleukin-21 in HBV infection: friend or foe?

Authors:  Yongyin Li; Libo Tang; Jinlin Hou
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

2.  Impact of weight reduction program on serum alanine aminotransferase activity and immunologic response in obese hepatitis B patients.

Authors:  Shehab Mahmoud Abd El-Kader; Mohammed H Saiem Al-Dahr
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

Review 3.  New therapeutic vaccination strategies for the treatment of chronic hepatitis B.

Authors:  Jia Liu; Anna Kosinska; Mengji Lu; Michael Roggendorf
Journal:  Virol Sin       Date:  2014-01-17       Impact factor: 4.327

Review 4.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

5.  New Gene Variants Associated with the Risk of Chronic HBV Infection.

Authors:  Mengjie Fan; Jing Wang; Sa Wang; Tengyan Li; Hong Pan; Hankui Liu; Huifang Xu; Daria V Zhernakova; Stephen J O'Brien; Zhenru Feng; Le Chang; Erhei Dai; Jianhua Lu; Hongli Xi; Yanyan Yu; Jianguo Zhang; Binbin Wang; Zheng Zeng
Journal:  Virol Sin       Date:  2020-04-15       Impact factor: 4.327

Review 6.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 7.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

Review 8.  Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections.

Authors:  Xuefen Li; Xia Liu; Li Tian; Yu Chen
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 9.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

Review 10.  Vaccine therapies for chronic hepatitis B: can we go further?

Authors:  Yumei Wen; Xuanyi Wang; Bin Wang; Zhenhong Yuan
Journal:  Front Med       Date:  2014-01-24       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.